Naz Rahman, an analyst from Maxim Group, maintained the Buy rating on Silexion Therapeutics (SLXN – Research Report). The associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback